Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran
Satar Rezaei, Maryam Bavandpour, Mohammadreza Mobinizadeh, Rajabali Daroudi · 2024
Read Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran by Satar Rezaei, Maryam Bavandpour, Mohammadreza Mobinizadeh, Rajabali Daroudi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11590557.txt.
Description
Rezaei, Bavandpour, Mobinizadeh, and Daroudi compare blood thinner options by cost effectiveness in Iran, in work from twenty twenty-four. Atrial fibrillation, a chaotic heart rhythm, raises stroke risk and needs anticoagulation. Newer drugs cost more than warfarin but need less monitoring.
Five options were compared: warfarin, apixaban, rivaroxaban, and dabigatran at two doses. A Markov model simulated patients over a lifetime from the Iranian payer perspective. Costs and health gains were weighed together. In developing health systems, such analysis decides which drugs a national formulary can afford to list for all patients.
Catalog record
| CREATOR | Satar Rezaei, Maryam Bavandpour, Mohammadreza Mobinizadeh, Rajabali Daroudi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |